譜尼測試(300887.SZ):武漢譜尼醫學檢驗實驗室獲批成為湖北省第二十三批核酸檢測機構
格隆匯 2 月 28日丨譜尼測試(300887.SZ)公佈,近日,譜尼測試集團股份有限公司下屬全資子公司武漢譜尼醫學檢驗實驗室(“武漢譜尼醫學”)接到湖北省新型冠狀病毒感染肺炎疫情防控指揮部通知,武漢譜尼醫學檢驗實驗室獲批成為湖北省第二十三批核酸檢測機構。武漢譜尼醫學檢驗實驗室具備新型冠狀病毒核酸檢測資質,可以開展新型冠狀病毒核酸檢測項目。
武漢譜尼醫學獲批成為新型冠狀病毒核酸檢測機構,能夠為客户提供便捷高效的核酸檢測服務,是公司拓展醫學檢測業務的有益嘗試,但截至目前武漢譜尼醫學尚未產生任何收入。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.